Therefore, the direct or indirect interaction among TP53, BRCA1, MDM4, and MYC can increase the tumor aggressiveness, and therapies targeting these pathways are promising strategies for treating IBC. The gene discussed is MDM4; the disease is inflammatory breast carcinoma.